Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D00TSX
|
||||
Former ID |
DNC006274
|
||||
Drug Name |
C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C47H59N13O7
|
||||
Canonical SMILES |
CCCCC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CCC(=O)N1<br />)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C<br />=C4)CC6=CN=CN6
|
||||
InChI |
1S/C47H59N13O7/c1-2-3-12-35-42(63)60-39(23-31-25-51-26-54-31)46(67)58-37(21-27-15-16-28-9-4-5-10-29(28)20-27)44(65)57-36(14-8-19-52-47(49)50)43(64)59-38(22-30-24-53-33-13-7-6-11-32(30)33)45(66)56-34(41(48)62)17-18-40(61)55-35/h4-7,9-11,13,15-16,20,24-26,34-39,53H,2-3,8,12,14,17-19,21-23H2,1H3,(H2,48,62)(H,51,54)(H,55,61)(H,56,66)(H,57,65)(H,58,67)(H,59,64)(H,60,63)(H4,49,50,52)/t34-,35-,36-,37+,38-,39-/m0/s1
|
||||
InChIKey |
AYKQERUAGGPJLP-WYLITWLFSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Melanocortin-4 receptor | Target Info | Inhibitor | [1] | |
Melanocortin-3 receptor | Target Info | Inhibitor | [1] | ||
Melanocortin receptor | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | ||||
Pathway Interaction Database | Syndecan-3-mediated signaling events | ||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (s) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
G alpha (s) signalling events | |||||
WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
Peptide GPCRs | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | J Med Chem. 2006 Mar 23;49(6):1946-52.Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.